Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 52 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMVExKM7:TR?= MXSwMVQh\A>? M322SIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2X6OFI3PzB{N{i0
HepG2 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u2bVAuOTBizszN NVW3fpJoOC12IHS= MlPBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVrtUmhiOjZ5MEK3PFQ>
HT29 MU\GeY5kfGmxbjDBd5NigQ>? NWTkUYttPTEEoH7N NHfzTGozPC15MjDo M364UYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> NELpOpIzPjdyMke4OC=>
HepG2 MoOySpVv[3Srb36gRZN{[Xl? NWDWPJY4PTEEoH7N NVfBcm9XOjRvN{KgbC=> M1Xkfolv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> NEHnWpgzPjdyMke4OC=>
HCC827 NVHm[nloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLPN3Y3PS95LkWvNVAhdk1? NXXpfHk{PzMEoHi= NEGwbWZFVVOR MYLlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NYe1dotnOjZ4N{W0PFQ>
A549  NH7KcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxNE8yPS9{MDDuUS=> MofEO|LDqGh? MnjhSG1UVw>? NGjI[FRmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= Mnf1NlY3PzV2OES=
NCI-H460  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXhNVAwOjBxM{Cgcm0> M1LOb|czyqCq Mk\QSG1UVw>? MVrlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NWHw[Io1OjZ4N{W0PFQ>
J89GFP NVzsUVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCN|ViTE2VT9Mg MW\FR|UxRTR7Lki1JOKyKDF{Lk[1JI5O M1HCbVI3PTZ|NU[4
THP89GFP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LzfGROW00EoB?= NYf6RnA5TUN3ME2xPU4{PCEEsTC2MlQ{KG6P NYnR[o9mOjZ3NkO1Olg>
SK-NEP-1 NVrINHZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPwNE4xOeLCk{GwMlAh|ryP NIS0O5ozPCCq NWTHSXZPTE2VT9Mg NW[2[XBDUUN3ME23Ok4{PCCwTR?= MVOyOlE4PjJzOR?=
G401 MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmexNE4xOeLCk{GwMlAh|ryP M{njfVI1KGh? MlriSG1UV8Li NXv5XIxSUUN3ME2xOFMvODJibl2= NEXJbIgzPjF5NkKxPS=>
SK-NEP-1 Ml7QR4VtdCCYaXHibYxqfHliQYPzZZk> MYi1NEBvVQ>? NFzYOW0y6oDVNDDk MULEUXNQyqB? NYrPZXR1emWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ M174VFI3OTd4MkG5
G401 M3HYOmNmdGxiVnnhZoltcXS7IFHzd4F6 MVG1NEBvVQ>? NHP3b2My6oDVNDDk MlnISG1UV8Li MW\y[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MW[yOlE4PjJzOR?=
SK-NEP-1 NHjwN5BCeG:ydH;zbZMhSXO|YYm= Mnj6OVAwOTByIH7N MoSxNlQhcA>? MX7EUXNQyqB? M2Twbolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHHFb4ozPjF5NkKxPS=>
G401 NFzSW2pCeG:ydH;zbZMhSXO|YYm= M17YZVUxNzFyMDDuUS=> M2XBNFI1KGh? M3yx[GROW00EoB?= MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEfLRZYzPjF5NkKxPS=>
SK-NEP-1 M4rWcGZ2dmO2aX;uJGF{e2G7 M1K3flUxNzFyMDDuUS=> NXfSN5lpOjRiaB?= NVG5c45RTE2VT9Mg MmLtd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? NXu3RmpkOjZzN{[yNVk>
G401 MmDXSpVv[3Srb36gRZN{[Xl? NWTle2VFPTBxMUCwJI5O Moj6NlQhcA>? NVzUOZllTE2VT9Mg MX;zbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v MoLlNlYyPzZ{MUm=
SK-NEP-1 NX;Vclh2TnWwY4Tpc44hSXO|YYm= MnH2OVAwOTByIH7N MYWyOEBp NXf0N29sTE2VT9Mg MUHpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> NIPiSlUzPjF5NkKxPS=>
G401 NXqxWpEyTnWwY4Tpc44hSXO|YYm= M4LRPVUxNzFyMDDuUS=> NH7YXZgzPCCq M3zQ[2ROW00EoB?= NYTHOpRjcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M1zWSFI3OTd4MkG5
RPMI 8226 MnLiR4VtdCCVdYL2bZZidCCDc4PhfS=> NYrzflZVOi92L{[gcm0> NH3u[Vk1QOLCiXi= NXj0bodocW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M1S3NVI3ODByMkmy
OPM2 NV;EO3pmS2WubDDTeZJ3cX[jbDDBd5NigQ>? M{TzUlIwPC94IH7N NUDtXWFsPDkkgJno MYnpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NYfmN2NEOjZyMECyPVI>
U266 Mm\vR4VtdCCVdYL2bZZidCCDc4PhfS=> MlnTNk81NzZibl2= M2LaUFQ56oDLaB?= Mmq4bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? M1S2UVI3ODByMkmy
H929 Mki0R4VtdCCVdYL2bZZidCCDc4PhfS=> Mnz5Nk81NzZibl2= M2PhXVQ56oDLaB?= M33He4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NELa[YkzPjByMEK5Ni=>
RPMI 8226  NF:4RnlCeG:ydH;zbZMhSXO|YYm= MmnROQKBkW6P NXTWcnJLOjRxNEigbC=> MnfRbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NWLERYhiOjZyMECyPVI>
HCC827 NUfkPZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zNVVExKG6P MV[0PEBp MXvEUXNQ MVHlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? M2rPelI2QTR2NkG3
NCI-H23 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPTc4dMOTBibl2= NI\kboI1QCCq MYrEUXNQ NHLNT3ZmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= M{\ZXVI2QTR2NkG3
AML3 MonWSpVv[3Srb36gRZN{[Xl? MYGwMVEh|ryP M1vC[lI1yqCq NXnsW5VPcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF3Ud5AzPTZzMkm0NS=>
ML-1 MV3GeY5kfGmxbjDBd5NigQ>? MWWwMVEh|ryP MofxNlTDqGh? M1fJOIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mmq1NlU3OTJ7NEG=
RPMI-8226vr10  MXjGeY5kfGmxbjDBd5NigQ>? NULG[msyOC1zIN88US=> M1rDNlI1yqCq MYrpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NY\uW2ZGOjV4MUK5OFE>
ML-1 MoXJSpVv[3Srb36gRZN{[Xl? NWPEZos{OSEQvF2= NYjRSIdoOjUEoHi= M2XvZYlv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk NIDSdpgzPTZzMkm0NS=>
RPMI-8226vr10  NVzNeoxRTnWwY4Tpc44hSXO|YYm= NXHpTHBPOSEQvF2= NInpWXQzPMLiaB?= NH2wUnBqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl MUSyOVYyOjl2MR?=
SK-N-BE (2) NVzXfHZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnhRXVCOjUkgJno Ml;PTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MmizNlU{ODh7MU[=
SK-N-BE (2), PAN  MK M2[2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36wXlI16oDLaB?= M{[1b2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MWeyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULFW2w4OjUkgJno MYXJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P NEfib|EzPTNyOEmxOi=>
SK-N-AS M{[xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTqPZIzPOLCiXi= NEXnXItKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= NFfmbHMzPTNyOEmxOi=>
SK-N-DZ MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTQ[5AzOjUkgJno MYLJR|UxRTF5LkJihKnDueLCiUCuOEBvVQ>? MV2yOVMxQDlzNh?=
Caki-1 NXXPTlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewWZE1OTBxMkWvOVAhdk1? NUjqVVVzPDhiaB?= M33DU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NWfEdpc3OjV{N{mxPVE>
ACHN M{XTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rQUFExNzJ3L{WwJI5O M4rZR|Q5KGh? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MlHBNlUzPzlzOUG=
769-P NWXLb4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTQNVAwOjVxNUCgcm0> NVewTI5PPDhiaB?= Mn;YbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NUnoOmFKOjV{N{mxPVE>
786-O  MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHkOotsOTBxMkWvOVAhdk1? MW[0PEBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NEPGTm8zPTJ5OUG5NS=>
Caki-1 NX;HXlRISXCxcITvd4l{KEG|c3H5 NFfoZ|c2OCCwTR?= MkjDOFghcA>? MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NEDTUXEzPTJ5OUG5NS=>
ACHN M335N2Fxd3C2b4Ppd{BCe3OjeR?= NInyOIc2OCCwTR?= M3XEWFQ5KGh? MmH3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NEDTbXczPTJ5OUG5NS=>
769-P MoX3RZBweHSxc3nzJGF{e2G7 NIj1Wok2OCCwTR?= NXX6[ZdwPDhiaB?= M3vkTolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NVT5b2NUOjV{N{mxPVE>
786-O  M3nvVWFxd3C2b4Ppd{BCe3OjeR?= M{TGV|UxKG6P M16wflQ5KGh? NXPpbGtocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MV6yOVI4QTF7MR?=
Caki-1 NIfkPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1NlUwPTBibl2= MUe0PEBp MnX1SG1UVw>? NI\iT3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NXPob3lqOjVzN{[zOVQ>
ACHN M17LXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWyOU82OCCwTR?= M3\KbFQ5KGh? NETIWJBFVVOR NWH6bY45cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NHThVJYzPTF5NkO1OC=>
769-P MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS5fVV2OjVxNUCgcm0> M1vzVFQ5KGh? NXLrNZNrTE2VTx?= MkXwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NV\kV41zOjVzN{[zOVQ>
Caki-1 NUnkbHFFS2:ub375JGZwem2jdHnvckBCe3OjeR?= M1fKNVUxKG6P Mm\0O{0yPCCm M3:yTWROW09? MVrzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> NW\3ZYhlOjVzN{[zOVQ>
ACHN M13DXWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M2rHZ|UxKG6P NH;sSZE4NTF2IHS= NWX0OIczTE2VTx?= NUPifINve3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MYKyOVE4PjN3NB?=
769-P NFz4TJREd2yxbomgSo9zdWG2aX;uJGF{e2G7 M1PGc|UxKG6P NICyWVU4NTF2IHS= NUHUWFRSTE2VTx?= MXHzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> NWPw[pZ2OjVzN{[zOVQ>
Caki-1 NXOyfnVySXCxcITvd4l{KEG|c3H5 NEnLS4c2OCCwTR?= NY\TS3lxPDhiaB?= MY\EUXNQ NIO5fJhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEju[XQzPTF5NkO1OC=>
ACHN MXLBdI9xfG:|aYOgRZN{[Xl? NVvw[Yg4PTBibl2= MmP0OFghcA>? NYrmems4TE2VTx?= Mm\XbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUWyOVE4PjN3NB?=
769-P M1v3R2Fxd3C2b4Ppd{BCe3OjeR?= NU[4UYxiPTBibl2= NWi5bXFkPDhiaB?= NVXkXVNLTE2VTx?= MonxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWXkdW9LOjVzN{[zOVQ>
MDA-MB-231 NYG5RpZ5VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MUCxNOKhdk1? NFPx[Ys{yqCm MoD4SG1UVw>? NXTIVIJD[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MWKyOFgyODR7Nx?=
BT-549 M13CXm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NIqwPI0yOMLibl2= Mn\YN:Kh\A>? MWLEUXNQ MoDDZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MWWyOFgyODR7Nx?=
MCF-7  M{nTNm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NUfx[JVIOTEEoH7N M3XJe|PDqGR? NUDqdIJHTE2VTx?= M2fmZ4FtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MXGyOFgyODR7Nx?=
MCF-7 MWLGeY5kfGmxbjDBd5NigQ>? MXu1MVUxKG6P Mny3NlQhcA>? MmjwSG1UVw>? M{HtW5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> NGTHSXczPDN4NkSwOy=>
CTS NYjSUYU4SXCxcITvd4l{KEG|c3H5 MVSw5qCUPDBibl5CpC=> MnzZOFghcA>? M4D6fYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXjlN2VWOjR{NES0Nlk>
OCI-AML3  M{nWbGFxd3C2b4Ppd{BCe3OjeR?= M3zORVDjiJN2MDDuUeKh NVHjXlB1PDhiaB?= MWjpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWSyOFI1PDR{OR?=
U937 NYDOcHhNSXCxcITvd4l{KEG|c3H5 NGTLXZIx6oDVNECgcm3DqA>? NYHWOJBlPDhiaB?= NYXmU5BncW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHzGcZkzPDJ2NESyPS=>
PC3 M4TDe2Fxd3C2b4Ppd{BCe3OjeR?= Mmi0NE0yODBibl2= MW[yOE81QCCq MorZbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlKxNlQyPjN{M{C=
PC3-AR NEnRWJFCeG:ydH;zbZMhSXO|YYm= MV[wMVExOCCwTR?= NXi3SYpUOjRxNEigbC=> MorRbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz M4LvdFI1OTZ|MkOw
PC3 NX3qe3NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5T|AuOTByIH7N Mmq3NlQwPDhiaB?= M1rkc4lv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? NI\xW2kzPDF4M{KzNC=>
PC3-AR NH;5U|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMVExOCCwTR?= MY[yOE81QCCq NYPTV2ZrcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|JOKHCqYYPl NIrtU5ozPDF4M{KzNC=>
PC3 NV3lTW8{TnWwY4Tpc44hSXO|YYm= Mmn3NE0yODBibl2= NXPudFEyOjRiaB?= MoT3d5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NGPSdHozPDF4M{KzNC=>
PC3-AR NGLsW4lHfW6ldHnvckBCe3OjeR?= NVHH[mlTOC1zMECgcm0> MonPNlQhcA>? MkDnd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MXmyOFE3OzJ|MB?=
OS-RC-2 NGDNd3RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYnOOZIyOC1zMECwJI5O NHGwWI8zPC92OD:3NkBp NHT3c4tFVVOR MlXP[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoqwNlQyPDR5M{e=
OS-RC-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL5bFYyPTBibl2= NWHJdFhWPDhiaB?= MYXEUXNQ MmLYbY5lfWOnczDHNk9OKGG{cnXzeC=> NGrTTIQzPDF2NEezOy=>
OS-RC-2 M4\VNWFxd3C2b4Ppd{BCe3OjeR?= MVO1NEBvVQ>? NFnFSmo1QCCq MnrUSG1UVw>? M1\UNolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1HHN|I1OTR2N{O3
SK-N-AS NXzJd48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonFNQKBmzhyIH7N MWO0PEBp M4njcWlEPTB;MkeuOEBvVQ>? NEjnVmQzPDB7OEe5PS=>
SK-N-DZ NHXET2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHiUIpNOOLCk{iwJI5O Moe2OFghcA>? Mnm2TWM2OD1{MT65JI5O M{flUVI1ODl6N{m5
SK-N-SH Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2w5qCUQDBibl2= MX60PEBp MYPJR|UxRTd{LkOgcm0> M17IOFI1ODl6N{m5
SK-N-BE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLvNQKBmzhyIH7N Ml\XOFghcA>? M3HKW2lEPTB;N{WuOEBvVQ>? NV\xWJZjOjRyOUi3PVk>
SK-N-AS NX\POWhiSXCxcITvd4l{KEG|c3H5 Mn;DNQKBmzhyIH7N M1GwZlQ5KGh? Mne3dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u M1\uTFI1ODl6N{m5
SK-N-DZ M4LNeGFxd3C2b4Ppd{BCe3OjeR?= MkTINQKBmzhyIH7N NHvBd4E1QCCq MYPwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M{jXR|I1ODl6N{m5
SK-N-SH MnzFRZBweHSxc3nzJGF{e2G7 M{XtSFDjiJN2MDDuUS=> NFn4flI1QCCq NXTpfo1beG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NVPGcY9QOjRyOUi3PVk>
SK-N-BE MX3BdI9xfG:|aYOgRZN{[Xl? NIT1NoMx6oDVNECgcm0> MYi0PEBp NFrTdpJxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MXOyOFA6QDd7OR?=
SK-N-AS NWeySnc1TnWwY4Tpc44hSXO|YYm= NHfuZ|Ix6oDVOECgcm0> NHv0dpU1QCCq MVjpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NX;1OG03OjRyOUi3PVk>
SK-N-DZ M3LLbWZ2dmO2aX;uJGF{e2G7 MYGw5qCUQDBibl2= NFTSXGw1QCCq NGCzSG9qdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MVGyOFA6QDd7OR?=
SK-N-SH NHG0VI1HfW6ldHnvckBCe3OjeR?= MWWw5qCUPDBibl2= MUG0PEBp MXHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MkjnNlQxQTh5OUm=
SK-N-BE MXrGeY5kfGmxbjDBd5NigQ>? MYew5qCUPDBibl2= MmTIOFghcA>? NWjQUJVscW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MWGyOFA6QDd7OR?=
HCC-LM3 NFTnVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULW[lY1OS1zMECwJI5O NIn4dVUzPC92OD:3NkBp MXLEUXNQ MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYTle25qOjRyOUO5OVY>
HepG2 NYTiZ4NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GNU0yODByIH7N NFLLSWozPC92OD:3NkBp M4X2d2ROW09? NV;ndJlycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH7lXIszPDB7M{m1Oi=>
SMMC-7721 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXVNU0yODByIH7N NF;4Z|UzPC92OD:3NkBp MkXCSG1UVw>? NVGxU5dUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnzFNlQxQTN7NU[=
HCC-LM3 MVrBdI9xfG:|aYOgRZN{[Xl? MYq1NEBvVQ>? M3rOd|Q5KGh? MlzwSG1UVw>? MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NXfQdWRuOjRyOUO5OVY>
HepG2 M2HROmFxd3C2b4Ppd{BCe3OjeR?= NGrobJQ2OCCwTR?= MnvwOFghcA>? M2nqNmROW09? NFvBS5NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NWTOPHZ{OjRyOUO5OVY>
SMMC-7721 MmXGRZBweHSxc3nzJGF{e2G7 NGfPNVk2OCCwTR?= NVPI[5dHPDhiaB?= NYDBVJpyTE2VTx?= NYr5VlFycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NF\DcpkzPDB7M{m1Oi=>
HCC-LM3 MoLOSpVv[3Srb36gRZN{[Xl? NHroWZE2OC9zMECgcm0> NV;kUWI6OjRiaB?= NHqyZ3hFVVOR NVzsPXJo\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> Moq2NlQxQTN7NU[=
HepG2 MXPGeY5kfGmxbjDBd5NigQ>? MXG1NE8yODBibl2= M4XYZVI1KGh? MYDEUXNQ M3TINYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= M{LBclI1ODl|OUW2
SMMC-7721 NGHSSGNHfW6ldHnvckBCe3OjeR?= NXfsOIp5PTBxMUCwJI5O MUOyOEBp NH3Bc|FFVVOR NUnDVmQ5\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MX:yOFA6Ozl3Nh?=
HCC-LM3 M4\VZWZ2dmO2aX;uJGF{e2G7 NVvhXFM4PTBxMUCwJI5O NXTRTFZ{OjRiaB?= NGPwNXVFVVOR M1TtdYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NUGzWZVOOjRyOUO5OVY>
HepG2 NYC3[YhqTnWwY4Tpc44hSXO|YYm= M3[wfVUxNzFyMDDuUS=> M4rUWlI1KGh? M3LzTmROW09? MVjkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v NYC1ZWxbOjRyOUO5OVY>
SMMC-7721 NIrKOpVHfW6ldHnvckBCe3OjeR?= Mm\FOVAwOTByIH7N NEf3eFMzPCCq MmTZSG1UVw>? MmHt[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? M2P0RlI1ODl|OUW2
FaDu MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzRU2wyODEkgJXuUS=> NYHkZWo5QC9zMD:xNkBp MVrkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? MXSyOFAzPjR6Mh?=
FaDu M{Tic2Z2dmO2aX;uJGF{e2G7 M4XWdlExOOLChX7N MWOyM|QwQC9zMjDo M1S0bYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NIW4XHIzPDB{NkS4Ni=>
PC-3  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCwMVExKM7:TR?= NIrK[GUzPC92OD:3NkBp NEDXR|VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGLLUG0zOzl7MUKxOi=>
LNCaP NYL5e2NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjjT5cxNTVizszN M2jhcVI1NzR6L{eyJIg> NXrnb|RjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVW2VHNkOjN7OUGyNVY>
RWPE-1  Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG1NE0zOCEQvF2= MXOyOE81QC95MjDo M16ycIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUCyN|k6OTJzNh?=
Capan-1 NUDsTmZqTnWwY4Tpc44hSXO|YYm= NHLWdWkzPS93MD:xNFAhdk1? M{DPdVgwOjRxNEigbC=> MWDEUXNQ NUfGUY11\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NEm1RoQzOzl{Mki4Oi=>
L3.6pl MUHGeY5kfGmxbjDBd5NigQ>? MVqyOU82OC9zMECgcm0> MYG4M|I1NzR6IHi= M33XU2ROW09? Moji[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MXuyN|kzOjh6Nh?=
CFPAC-1  MonQSpVv[3Srb36gRZN{[Xl? NUfsZm86OjVxNUCvNVAxKG6P NH73UmQ5NzJ2L{S4JIg> NWL1R3A4TE2VTx?= MoLn[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NX\VN|BROjN7MkK4PFY>
Capan-1 NWDwPIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMNlUwPTBxMUCwJI5O NVzYS3pTPDhiaB?= NVjUWFJpTE2VTx?= M4PhOpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXnoTI1[OjN7MkK4PFY>
L3.6pl M1jDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyOU82OC9zMECgcm0> NYS3bm9yPDhiaB?= NHPLXplFVVOR M2LTNpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3S1XlI{QTJ{OEi2
CFPAC-1  NWfVRppmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\SSYJbOjVxNUCvNVAxKG6P MV[0PEBp M{Tne2ROW09? MmnDdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUKyN|kzOjh6Nh?=
Capan-1 NYjOfI9PSXCxcITvd4l{KEG|c3H5 NWLsOXJTOjVxNUCvNVAxKG6P MoCzOFghcA>? M{K0W2ROW09? M3PtTIlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NICzb2czOzl{Mki4Oi=>
L3.6pl M1jIS2Fxd3C2b4Ppd{BCe3OjeR?= NWfJe5pSOjVxNUCvNVAxKG6P MVm0PEBp NITGflNFVVOR MUfpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MknvNlM6OjJ6OE[=
CFPAC-1  NVe2SnhiSXCxcITvd4l{KEG|c3H5 NY\FdFZ1OjVxNUCvNVAxKG6P M1nuSFQ5KGh? NX71SW5STE2VTx?= MYLpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NES4cXczOzl{Mki4Oi=>
HN22 M4TKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMVIxKG6P MYOyOE81QCCq MnPBSG1UVw>? MnPUbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NX\0TnRFOjN6N{eyN|U>
HSC4  M1jXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r4dFAuOjBibl2= NXv1SoNsOjRxNEigbC=> M2O1O2ROW09? MlfobY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M2nRNVI{QDd5MkO1
HN22 MVHBdI9xfG:|aYOgRZN{[Xl? M2XUUlAuOjBibl2= NWDWbHNQPDhiaB?= M1TKbmROW09? MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYTteHFqOjN6N{eyN|U>
HSC4  MYnBdI9xfG:|aYOgRZN{[Xl? NHrqVoMxNTJyIH7N MUe0PEBp NVXkNJBsTE2VTx?= Mn[zbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUeyN|g4PzJ|NR?=
HN22 NI\SN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTLWlUxNTJyIH7N M13MdFQ5KGh? MUHEUXNQ NEDpdppqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> MXWyN|g4PzJ|NR?=
HSC4  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMVIxKG6P M320WFQ5KGh? NFPvSGJFVVOR NHqySHlqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> NWr2fXpUOjN6N{eyN|U>
HN22 MWTGeY5kfGmxbjDBd5NigQ>? MVqwMVIxKG6P MVm0PEBp NUDWN|JoTE2VTx?= NEi3[nF{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> MUSyN|g4PzJ|NR?=
HSC4  MXzGeY5kfGmxbjDBd5NigQ>? MnX5NE0zOCCwTR?= NFTwSoc1QCCq MWjEUXNQ MXzzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NYrFRpFwOjN6N{eyN|U>
Cal62 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS1NphGUUN3ME2zN{DDuSB2IH7N NUCyR3JHOjN6MkSwOlQ>
Hth7 NWn2XHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7ROGtLUUN3ME2xOUDDuSB{IH7N MlW4NlM5OjRyNkS=
Hth83 M1PnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1|NDFCtUA2KG6P Mo[1NlM5OjRyNkS=
C643 M{fSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnBTWM2OD15MTFCtUAyOCCwTR?= NWHhN4tiOjN6MkSwOlQ>
SW1736 NXnJW3RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN3INMxJFghdk1? MYGyN|gzPDB4NB?=
T241 M2OzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTZ3INMxJFchdk1? M2HLPFI{QDJ2ME[0
T351 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33V|BRUUN3ME21NEDDuSBzMDDuUS=> NX7le5VmOjN6MkSwOlQ>
BHP2-7 NEi3TplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm5TWM2OD1|NzFCtUA3KG6P MYqyN|gzPDB4NB?=
T238 NF\vdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFuNUCwJOKyKDJyMDDuUS=> M2XtNlI{QDJ2ME[0
HCT8 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLE[GQ4OiCq NF3QO3pFVVOR MX3JR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? NWrkUHJDOjN{OUmzPFg>
H630 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rNTFczKGh? MVvEUXNQ M{fnNWlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P NFfibHEzOzJ7OUO4PC=>
cH630 5-FU-res Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfBR|Y4OiCq MX3EUXNQ MVvJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? NH7lVZgzOzJ7OUO4PC=>
HCT116 NGrUcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\DbGlNPzJiaB?= MUfEUXNQ NF7nO2pKSzVyPUGwMlfjiIoEsfMAjVIvOiCwTR?= M{i2blI{Ojl7M{i4
HCT116 p53−/− M1zpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXt[284OiCq MXfEUXNQ M3:xSWlEPTB;OD625qCKyrIkgJmxMlchdk1? NHX1VmQzOzJ7OUO4PC=>
dHCT116 p21−/− M17KSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD4O|IhcA>? MW\EUXNQ MYXJR|UxRTVwOfMAjeKy6oDLMT6zJI5O MkmwNlMzQTl|OEi=
HT29 NH;qRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjKbmU4OiCq NIPw[2pFVVOR M3zCW2lEPTB;MU[uN-KBkcLz4pEJNk4{KG6P M{TVbFI{Ojl7M{i4
LoVo NGf5enBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzj[JI4OiCq NVftS5JQTE2VTx?= MUnJR|UxRTVwMfMAjeKy6oDLMD62JI5O NIHqOG4zOzJ7OUO4PC=>
RKO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LLclczKGh? MXvEUXNQ Mnu5TWM2OD15LkpihKnDueLCiUKuNkBvVQ>? M335R|I{Ojl7M{i4
SW480 NHXEfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr0O|IhcA>? Mn;GSG1UVw>? MXjJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? MWWyN|I6QTN6OB?=
eSW620 NXnTbWdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\WO|IhcA>? M3ixXGROW09? M4\qbmlEPTB;OT6x5qCKyrIkgJmyMlEhdk1? MXSyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Cancer Center September 2018 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) February 8 2018 Phase 2
NCT02961816 Withdrawn Lymphoma M.D. Anderson Cancer Center June 2017 Phase 2
NCT02802163 Withdrawn Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen June 2017 Phase 1|Phase 2
NCT02756663 Withdrawn Multiple Myeloma Novartis Pharmaceuticals|Novartis December 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID